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ORIGINAL ARTICLE
Oxytocin increases eye contact during a real-time, naturalistic
social interaction in males with and without autism
B Auyeung1,2, MV Lombardo2,3,4, M Heinrichs5,6, B Chakrabarti2,7, A Sule8, JB Deakin9,10, RAI Bethlehem2, L Dickens2, N Mooney2,
JAN Sipple2, P Thiemann2 and S Baron-Cohen2,10
Autism spectrum conditions (autism) affect ~1% of the population and are characterized by deﬁcits in social communication.
Oxytocin has been widely reported to affect social-communicative function and its neural underpinnings. Here we report the ﬁrst
evidence that intranasal oxytocin administration improves a core problem that individuals with autism have in using eye contact
appropriately in real-world social settings. A randomized double-blind, placebo-controlled, within-subjects design is used to
examine how intranasal administration of 24 IU of oxytocin affects gaze behavior for 32 adult males with autism and 34 controls in a
real-time interaction with a researcher. This interactive paradigm bypasses many of the limitations encountered with conventional
static or computer-based stimuli. Eye movements are recorded using eye tracking, providing an objective measurement of looking
patterns. The measure is shown to be sensitive to the reduced eye contact commonly reported in autism, with the autism group
spending less time looking to the eye region of the face than controls. Oxytocin administration selectively enhanced gaze to the
eyes in both the autism and control groups (transformed mean eye-ﬁxation difference per second = 0.082; 95% CI:0.025–0.14,
P= 0.006). Within the autism group, oxytocin has the most effect on ﬁxation duration in individuals with impaired levels of eye
contact at baseline (Cohen’s d= 0.86). These ﬁndings demonstrate that the potential beneﬁts of oxytocin in autism extend to a real-
time interaction, providing evidence of a therapeutic effect in a key aspect of social communication.
Translational Psychiatry (2015) 5, e507; doi:10.1038/tp.2014.146; published online 10 February 2015
INTRODUCTION
Autism spectrum conditions (henceforth autism) are characterized
by deﬁcits in social communication alongside unusually narrow
interests and repetitive behaviors. There are currently few
effective behavioral or pharmacological treatments that can
ameliorate core social difﬁculties associated with autism. Little is
also known about how treatments may be effective for subgroups
within autism; so far, none have been developed with speciﬁcity in
mind for targeting a speciﬁc subset of behaviors that individuals
on the autism spectrum may have particular difﬁculty with. One
exemplar domain of social behavior that would be a critical target
for treatments is eye gaze behavior and processing gaze
information of others. Eye gaze is observed to be atypical in
many cases of autism from early infancy and persists into
adulthood.1–5 Developmentally, sensitivity to information from
the eyes and appropriate use of gaze behavior in social contexts
may also provide an important platform for later development of
more complex social-cognitive abilities that are requisite for
further development of social cognition and behavior.6,7 Given the
importance of gaze processing and behavior, treatments that can
target this aspect of the phenotype may offer much help to
individuals with autism.
One candidate pharmacological target of much current interest
for autism and social behavior is the neuropeptide oxytocin. A
large body of research across human and nonhuman species has
demonstrated a role for oxytocin in social behavior and
cognition.8–16 One example of this is seen in oxytocin’s inﬂuence
on eye gaze behavior. Oxytocin administration has been shown to
increase gaze toward the eye region of static photographs of the
face,14 and also increases orienting of attention to gaze cues.17
fMRI studies have also found that oxytocin exerts inﬂuence on
important neural circuits for a wide range of social-cognitive
abilities such as gaze, mentalizing, emotion-recognition and
learning.11,18–25 Oxytocin has also been evaluated in studies of
autism, and has been shown to have a broad impact on an array of
important behaviors and neural systems.10,26–30 Abnormalities in
genetic variation of the oxytocin receptor,13,31 as well as animal
models32 have also provided evidence that oxytocinergic
abnormalities exist in autism.
However, despite the mounting evidence for the importance of
oxytocin as a potential pharmacological target for further
development in terms of how it might affect aspects of social
behavior in autism, all of the work until now has been based on
studies done in constrained laboratory settings. These studies are
obviously necessary and critical. However, for furthering the
translational process, there is also a need to test whether the
effects of oxytocin can have substantial impact on social-
communicative behavior in more naturalistic real-world social
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contexts. In addition, translational progress must be made for
examining how oxytocin may or may not be effective for certain
individuals and to better characterize who might beneﬁt the most
from oxytocin.
The present study aims to address these issues by evaluating
the effect of oxytocin on gaze behavior during a naturalistic live,
real-life social interaction with another person. Furthermore, we
examined how oxytocin might be more or less effective in
subgroups of individuals with autism who exhibited either below
average eye contact (relative to the control group), intact, or
above average eye contact under baseline placebo conditions.
MATERIALS AND METHODS
A randomized, double-blind, placebo-controlled, within-subjects design
was used. Independent pharmacists dispensed either an active or placebo
spray according to a computer-generated randomization list. Participants
received an active intranasal oxytocin spray (24 IU, 40.32 µg, Syntocinon-
spray; Novartis, Switzerland), three actuations administered to each nostril,
(4I U, 6.72 µg each) or a placebo containing the same ingredients with the
exception of the active oxytocin, on two visits separated by 1 week. The
single 24 IU dose was selected on the basis of ﬁndings from earlier studies
of oxytocin and behavior suggesting that a similar dose of oxytocin could
enhance social behavior compared with placebo (for reviews, see Heinrichs
et al.13 and Meyer-Lindenberg et al.33).
Participants
Males 18–56 years of age (M= 34.23, s.d = 9.18) were included in this study.
The clinical group consisted of 37 males with a diagnosis of Autism or
Asperger Syndrome based on strict DSM-IV criteria.34 Thirty-seven typically
developing males were recruited from the University of Cambridge and the
general population. Exclusion criteria included smoking; a diagnosis of
major depression, bipolar, obsessive–compulsive, panic or psychotic
disorder; use of any psychoactive medication within one year of the
study; substance dependence; or epilepsy. Women were excluded to avoid
sex differences in oxytocin response.9,12
Measure
The study evaluated naturalistic social behavior during a semi-structured
interview with a researcher at a remote location, facilitated by video link.
This allowed the use of eye tracking with a Tobii T120 binocular infrared
eye tracker, which records the x and y coordinates of the participant's eye
position using corneal reﬂection techniques. The camera is embedded in a
17-inch thin-ﬁlm transistor LCD monitor (1280× 1024 pixels resolution),
promoting more naturalistic participant behavior since it does not place
restraints on participants such as a head mount or glasses. The eye tracker
samples the position of the eyes at a rate of 120 Hz, with an average
precision of within 0.5-degree visual angle.35
At both the visits, participants were asked questions about their well-
being, their journey to the research center, how the nasal spray made
them feel, attitudes towards participating in research and what they liked
and did not like about the study.
At the interviewer’s location, the camera was positioned directly ahead
of the screen so as to be level with the image of the participant’s eye level.
The interviewer was trained to look directly into the camera to ensure that
the participant perceived the interviewer was providing eye contact. The
same researcher performed the interviews for both visits. Considerable
attention was given to ensuring consistency in the visual appearance of
the interviewer between visits, and a plain white background was used to
minimize the potential for visual distraction.
Following completion of the interview, moving areas of interest (AOIs)
were drawn around the eyes, mouth, or other non-eye-or-mouth face areas
using the ‘Dynamic AOI (area of interest)’ tool, using freeform shapes in
Tobii Studio.35 The dynamic AOIs move with the interviewer’s face in real
time. See Figures 1a for a representation of the study setup. Figure 1b
shows examples of the AOIs drawn for the eyes, mouth and other non-eye-
or-mouth regions. Measures included ﬁxation count (number of gaze
ﬁxations toward an AOI) and gaze duration (total milliseconds spent
ﬁxating on an AOI).35
Procedure
The participants were instructed to abstain from alcohol and caffeine on
the day of testing and from food and drink, except water, for 2 h before
spray administration.
Upon arrival, a medical examination including measurements of blood
pressure, heart rate and general well-being was conducted. A medical
professional provided a prescription and remained in attendance to
manage any potential ill effects from the spray. The participants received
either the active or placebo nasal spray (three puffs per nostril, alternating
between sides) and were asked to wait for 45min9 before being asked to
complete a questionnaire and a series of computer-based tasks, lasting
~35min.
The participants were then asked to speak to a researcher at a remote
location about their experience with the study, and the interaction was
initiated as a semi-structured interview via video link designed to last
~5min. At the end of the session, the participants were asked to complete
a ‘Wellness’ questionnaire that asked about side effects that the
participants may have experienced. The same experimenter conducted
the interview for both visits.
Figure 1. Experimental setup and areas of interest (AOI). (a) Depicts the study setup. (b) Shows the AOIs drawn for the eyes, mouth and other
non-eye-or-mouth regions.
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Written consent was obtained before and during the visit. Ethical
approval was provided by the UK National Research Ethics Service. This
study was exempt from clinical trials status by the UK Medicines and
Healthcare products Regulatory Agency.
Data analysis
The number of ﬁxations and total ﬁxation duration were examined for the
eyes, mouth and other non-eye-or-mouth face areas using Tobii Studio
software (version 3.2.1). The Tobii I-VT ﬁlter (classiﬁer: 30° per second;
Velocity calculator window length: 20 ms) was used to identify ﬁxations. No
gap-ﬁlling or other noise reduction technique was used. Minimum ﬁxation
duration was 60ms. Maximum time between ﬁxations classiﬁed as
separate ﬁxations was 75ms. Data were normalized for length of interview
as follows:
Normalized number of ﬁxations (per second) =Number of ﬁxations/
Interview time
Normalized ﬁxation time (proportion) = Total ﬁxation time/
Interview time
A square-root transformation was employed for all the data as they were
positively skewed. The transformed data approximated the normal
distribution, and transformed data were used in all subsequent analyses.
A repeated-measures analysis of variance (ANOVA) was conducted for a
possible three-way interaction between drug (two levels—oxytocin and
placebo), AOI (three levels—eyes, mouth other non-eye-or-mouth face
areas) and group (two levels—autism and controls). For signiﬁcant
interactions, separate follow-up repeated-measures ANOVAs for each
region were conducted to discern the nature of the interaction. For
signiﬁcant interactions, tests within each variable were used to character-
ize the nature of the interaction.
Finally, the autism group was subdivided to evaluate whether oxytocin
had a greater effect on individuals with lower eye contact (measured by
ﬁxations to the eye region of the face). Subgroups with ‘Low’ and ‘High’
eye contact were deﬁned by comparing measured values with the mean
score from the control group under placebo, objectively classifying each
individual as having lower or higher looking than the average control
participant. Individuals with autism were allocated to the ‘Low’ group
where they scored below the control group mean with both placebo and
oxytocin, and to the ‘High’ group where they scored above this value with
both placebo and oxytocin. Individuals who had scores from each
condition, which fell both above and below the control group mean were
not included in this analysis, as these individuals could not be clearly
classiﬁed as belonging to the ‘Low’ or ‘High’ group. A ‘difference score’ of
oxytocin—placebo was then computed for the eye AOI. Independent
samples t-tests with bootstrapping (10 000 resamples) were used to
compare the ‘Low’ versus ‘High’ subgroups using this difference score.
RESULTS
Several participants were excluded from the ﬁnal analysis. In the
control group, one participant did not attend the second visit, and
there was a technical malfunction for two participants. In the
autism group, three participants did not attend the second visit,
and there was a technical malfunction for two participants. The
ﬁnal data set consisted of 34 control males and 32 males with
autism, matched on age and IQ (intelligence quotient using the
Wechsler Abbreviated Scale of Intelligence). See Table 1 for
descriptive information.
Case–control analysis for looking preferences (placebo only)
To look at general group differences, comparisons were made
between cases and controls under the placebo condition only.
Independent samples t-tests were conducted, and the means,
standard deviations, range, t-test and P-values are presented in
Supplementary Table 1.
Individuals with autism (M= 0.59, s.d. = 0.38) show signiﬁcantly
fewer ﬁxations than controls (M= 0.83, s.d. = 0.34) to the eye
region of the face, t(64) = 2.660, P= 0.010, Cohen’s d= 0.666.
However, no signiﬁcant group differences were observed for the
mouth or non-eye-or-mouth face regions. Figure 2 shows the
number of ﬁxations (normalized for interview length) for the eyes,
mouth and non-eye-or mouth face areas of interest. Error bars
indicate 95% conﬁdence intervals.
There was also a signiﬁcant difference t(64) = 2.454, P= 0.017,
Cohen’s d= 0.581 in looking time to the eye region of the face.
Individuals with autism showed lower proportion of total looking
time to the eyes (M= 0.32, s.d. = 0.23) than controls (M= 0.44, s.
d. = 0.18). There were no group differences in looking time to the
mouth or the non-eye-or-mouth regions (P40.05).
Effect of oxytocin—number of ﬁxations
To understand the relationship between group, drug and looking
preferences, a three-way repeated-measures ANOVA was ﬁrst
performed using the transformed data. The three-way ANOVA
interaction between drug×AOI × group was not signiﬁcant (Wilks’
Lambda= 0.989, F(2,63) = 0.352, P= 0.705, partial η2 = 0.011). The
two-way interaction between AOI × group was also not signiﬁcant
(Wilks’ Lambda = 0.952, F(2,63) = 1.590, P= 0.212, partial
η2 = 0.048). However, the drug ×AOI interaction was signiﬁcant
(Wilk’s Lambda = 0.899, F(2,63) = 3.544, P= 0.035, partial η2 = 0.101,
Table 1. Participant characteristics
Variable Autism group (n= 32) Control group (n= 34) Group differences
Mean s.d. Range Mean s.d. Range t P-value
Age 36.04 9.36 18.50–56.00 32.80 9.35 21.17–52.92 1.447 0.153
Verbal IQ 110.44 15.13 75–147 110.82 17.63 67–140 0.030 0.976
Performance IQ 120.25 12.12 89–138 122.34 8.22 102–136 0.967 0.337
Full IQ 116.84 12.85 85–147 118.06 11.47 94–141 0.476 0.636
Abbreviation: IQ, intelligence quotient using the Wechsler Abbreviated Scale of Intelligence.
Figure 2. Number of ﬁxations for each AOI by group (normalized for
interview length). AOI, area of interest.
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Cohen’s d= 0.670). This suggested that there was an effect of drug
on speciﬁc AOIs. There was also a signiﬁcant effect for the
between-subjects factor (group) (F(1,64) = 6.219, P= 0.015, partial
η2 = 0.089). Figure 3 shows the number of ﬁxations for each AOI
by drug.
Follow-up tests for each AOI show a signiﬁcant main effect of
drug for the eye region (F(1,65) = 8.225, P= 0.006, partial
η2 = 0.112, Cohen’s d= 0.710), with a larger number of ﬁxations
under oxytocin (M= 0.797, s.d. = 0.358) than placebo (M= 0.7144, s.
d. = 0.377). No main effects were observed for the mouth region (F
(1,65) = 0.247, P= 0.621) or other non-face-or-mouth regions (F
(1,65) = 0.477, P= 0.492).
Total ﬁxation time
For total ﬁxation time, the three-way ANOVA interaction between
drug×AOI × group interaction was not signiﬁcant (Wilks’
Lambda= 0.999, F(2,63) = 0.025, P= 0.975, partial η2 = 0.001). The
two-way interaction between AOI × group was also not signiﬁcant
(Wilks’ Lambda = 0.968, F(2,63) = 1.028, P= 0.364, partial
η2 = 0.032). The drug×AOI interaction was signiﬁcant (Wilk’s
Lambda= 0.893, F(2,63) = 3.782, P= 0.028, partial η2 = 0.107,
Cohen’s d= 0.692), and suggested that there was an effect of
drug on speciﬁc AOIs. As for the number of ﬁxations, the between-
subjects factor (group) was also signiﬁcant (F(1,64) = 10.482,
P= 0.002, partial η2 = 0.141).
Follow-up tests for each AOI show a signiﬁcant main effect of
drug for the eye region (F(1,65) = 5.607, P= 0.021, partial
η2 = 0.079, Cohen’s d= 0.586), with longer looking times under
oxytocin (M= 0.421, s.d. = 0.199) compared with placebo
(M= 0.381, s.d. = 0.213). No main effects were observed for the
mouth region (F(1,65) = 1.666, P= 0.201) or other non-face-or-
mouth regions (F(1,65) = 0.754, P= 0.388).
Within-group analysis in autism
In the autism group, n= 18 participants had a number of ﬁxations
to the eye region which was below the control group placebo
mean (Low group) under both oxytocin and placebo, whereas, for
n= 11 participants, both scores were above this value (High
group). The effect of oxytocin was evaluated using ‘difference
scores’, calculated by subtracting the placebo value from the
oxytocin value. This analysis indicated no signiﬁcant difference in
oxytocin effect on the number of eye ﬁxations in the ‘Low’ group
(M= 0.134, s.d. = 0.148) compared with the ‘High’ group (M= 0.044,
s.d. = 0.180, t(27) = 1.467, bootstrapped P= 0.040, Cohen’s
d= 0.188).
For total ﬁxation time, n= 18 individuals with autism fell into the
‘Low’ group, with n= 9 individuals in the ‘High’ group. This
showed a greater effect for oxytocin in the ‘Low’ group difference
score (M= 0.059, s.d. = 0.087) compared with the ‘High’ group
(M=− 0.012, s.d. = 0.077), t(25) = 2.083, bootstrapped P= 0.037,
Cohen’s d= 0.864. These data are illustrated in Figure 4.
Figure 3. Normalized number of ﬁxations for each AOI by drug (data not transformed). (a) Shows ﬁxations to the eyes for each AOI by drug for
the control group. (b) Shows ﬁxations to the eyes for each AOI by drug for the autism group. Error bars show± 1 s.e.d. for this within-subjects
comparison. AOI, area of interest.
Figure 4. Difference scores in ﬁxation time for the ‘Low’ versus ‘High’
looking groups in autism (groups identiﬁed using control group
mean). CI, conﬁdence interval.
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Individuals who had scores in the oxytocin and placebo
condition that fell both above and below the control group mean
were not included in this analysis (n= 3). The difference scores for
these participants for the number of ﬁxations and ﬁxations time
were M= 0.241, s.d. = 0.376 and M= 0.146, s.d. = 0.248, respec-
tively, and suggest that the exclusion of these participants did not
bias the result.
Side effects
A record was kept of the side effects that the participants
experienced from the oxytocin or placebo nasal sprays. No serious
adverse effects were reported. Supplementary Table 2 shows the
number of participants in each group who reported each side
effect.
DISCUSSION
This double-blind, placebo-controlled study utilized a novel
measurement technique to evaluate the effect of oxytocin on
gaze behavior in autism (Figure 1). The design of the experiment
enabled gaze data to be collected during a real-time social
interaction, while also maintaining the repeatability necessary to
evaluate drug versus placebo effects. Findings from the baseline
(placebo) condition illustrate the reduced eye contact that is
frequently observed in autism (Figure 2). These ﬁndings are in
accordance with work showing reduced eye contact in autism,36
and suggest that the measure used is ecologically valid.
Both the oxytocin and placebo nasal sprays were successfully
administered to all of the participants, with few side effects
reported. Oxytocin was found to signiﬁcantly increase participant
gaze to the eye region of the interviewer’s face in both the autism
and control groups. This effect was signiﬁcant in both the number
of ﬁxations and the total ﬁxation time. Gaze to the mouth and
other regions of the face did not vary signiﬁcantly between the
autism and control groups, and was not affected by oxytocin
(Figure 3). Within the autism group, it was also found that oxytocin
had a greater effect on looking time in individuals who exhibited
lower eye contact in the placebo condition.
The ﬁndings in this study are supported by earlier work where
oxytocin was shown to increase gaze to the eye region of static
photographs in typical males14 and in autism.29 This latter study
also found that oxytocin promotes social behavior in a computer-
simulated ball game where the level of social interaction exhibited
by the other players was varied.29 In the present study, we found
that this beneﬁt can be extended to a real-life, naturalistic
discussion with another individual.
The group differences observed in gaze to the eye region also
replicate ﬁndings reported in clinical assessments, where eye
contact is substantially reduced in individuals with autism.37
Results within the autism group suggest that participants with the
lowest levels of eye contact could beneﬁt the most from oxytocin,
with a greater increase in time spent looking at the eye region of
the face (in line with a greater effect in autism versus controls).
However, this analysis is necessarily limited by the size of the
subgroups examined. It would be helpful to verify this ﬁnding in a
study where repeated baseline (placebo) measures are possible in
the autism group. It is also not known if these results would
extend to individuals with greater impairment, as the autism
group in this study only included individuals whose cognitive
functioning was intact.
The current data support a wider body of work suggesting that
neuropeptides have a role in everyday social behavior, and that
the intranasal administration of oxytocin is able to effect
measureable changes in brain and behavior. Interestingly, these
effects of oxytocin in enhancing gaze towards the eyes in a
naturalistic social interaction mimic the opposite effect previously
observed in a patient with amygdala lesions.38 Separately,
oxytocin was found to enhance reﬂexive gaze shifts towards the
eyes, which in turn were associated with increased amygdala
response.21 In combination with these ﬁndings, other evidence
pointing towards a role of oxytocin in amygdala-mediated neural
systems is growing.10,18,20,23,24,39 It has also been suggested that
oxytocin could reduce anxiety through amygdala-dependent
mechanisms,40,41 which may provide an additional beneﬁt in
social interactions.33
This study demonstrates that a single dose of oxytocin can have
an effect on eye contact within a relatively short time window. It is
not currently known whether this effect could be long lasting.
However, it has also been suggested that oxytocin could promote
longer lasting changes in social cognition such that when similar
situations are encountered again they will be both more
rewarding (through dopamine action) and more memorable
(through noradrenaline action).42 Further research is needed in
this area, though the concept may also be supported through
animal models of oxytocin action, which continue to evolve.42
Other work is also needed to help understand how the effects
observed in the present study might affect women, or translate
into different environments in men. In particular, it would be
useful to measure eye contact in other settings and with people
who the individuals with autism are familiar with. Further research
could also examine how oxytocin affects individuals who are more
severely impaired, and to look at whether the results obtained in
this study replicate in larger samples. The long-term effects of
oxytocin and possible side effects from repeated doses should be
examined.
In conclusion, this study demonstrates the potential for a single
dose of 24 IU intranasal oxytocin to increase gaze to the eye
region, an important marker for social communication difﬁculties
that are characteristic of autism. The effect was signiﬁcant within
both the autism and control groups, with those in the autism
group who spent less time looking to the eye region beneﬁting
the most from oxytocin administration. The study also demon-
strated the capability to quantitatively measure reduced eye
contact in male adults with autism by using a novel measure of
eye contact during a naturalistic social interaction. These results
suggest that this technique is an ecologically valid and sensitive
assay that demonstrates the inﬂuence of oxytocin on important
social behaviors for autism. With further research, it is hoped that
the current ﬁndings will assist the evaluation of oxytocin as a
potentially therapeutic agent for enhancing aspects of social
behavior in autism.
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